Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azemiglitazone - Metabolic Solutions Development Company

Drug Profile

Azemiglitazone - Metabolic Solutions Development Company

Alternative Names: MSDC-0602; MSDC-0602 potassium; MSDC-0602K

Latest Information Update: 05 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Cirius Therapeutics; Metabolic Solutions Development Company
  • Class Antihyperglycaemics; Hepatoprotectants; Insulin sensitisers; Small molecules; Thiazolidinediones; Urologics
  • Mechanism of Action Mitochondrial membrane transport protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Suspended Type 2 diabetes mellitus
  • No development reported Polycystic kidney disease

Most Recent Events

  • 05 Sep 2023 Chemical structure information added
  • 21 Jun 2023 Pharmacodynamics data from a phase IIb trial in Non alcoholic steatohepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)
  • 08 Sep 2021 Azemiglitazone is still in phase II trials for Non-alcoholic steatohepatitis in USA (Metabolic Solutions Development Company pipeline, September 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top